Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gemcitabine Combinations in Metastatic Breast Cancer
NCT00480597Phase 2Completed
- Sponsor
- Ludwig Maximilian University of Munich
- Start
- Oct 2002
- Modality
- DNA Intercalators/Alkylators, Irreversible Covalent Inhibitors, RNA-Targeting Small Molecules
01
Overview
Phase 2, randomised, open-label trial in breast cancer comparing Gemcitabine + Vinorelbine, Gemcitabine + Cisplatin and Gemcitabine + Capecitabine (3 arms). Primary endpoint: Overall Response Rate at 1 year. Started Oct 2002; status: completed.
02
Drugs
gemcitabinevinorelbinecisplatincapecitabine
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT00480597.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00480597.